Effects of 3% trehalose as an adjuvant treatment after LASIK

Abstract

PurposeTo evaluate the effect of 3% trehalose as an adjuvant in the standard treatment after laser-assisted in situ keratomileusis.DesignInterventional prospective comparative single-blind study.SettingDepartment of Ophthalmology, Hospital Quirón Zaragoza, Spain.MethodsA total of 26 eyes (13 patients) were included, of which 12 eyes (group 1) received conventional treatment with lubricant drops of hyaluronic acid (0.15%) and 14 eyes (group 2) received, additionally, an ophthalmic solution of 3% trehalose. Pre- and postoperative quality-of-life tests and vital stains, tear breakup time, and osmolarity measurements were made.ResultsWe obtained statistically significant differences between the groups in the Symptom Assessment in Dry Eye test in all visits with respect to severity, and in the postoperative day 1 visit with respect to frequency, in all cases favoring the trehalose treatment. The values of osmolarity were not significantly different between groups. However, we did find significant differences in the Oxford scale in day 90 for the trehalose treatment (P<0.001), and in the National Eye Institute scale in day 30 (P=0.02).ConclusionThe results of this exploratory study indicate that the adjuvant treatment with 3% trehalose could be superior with respect to the standard treatment, with improvements in the objective and subjective parameters of tear quality.

Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells

“…Trehalose is highly employed in cryopreservation studies as a nontoxic additive, capable of significantly reducing the concentration of permeable cryoprotectants (e.g., Me 2 SO) or even excluding it from the freezing medium [2, 50, 51]. The positive effect of trehalose has been shown in ophthalmological studies to improve corneal regeneration after acute corneal damage [52] or dry eye syndrome [53]. We have previously shown that trehalose is a very potent therapeutic agent in corneal regeneration, which favourably influences the oxidative damage of the cornea and suppresses proinflammatory cytokine production [49, 52, 54].…”

Autophagy Upregulation by the TFEB Inducer Trehalose Protects against Oxidative Damage and Cell Death Associated with NRF2 Inhibition in Human RPE Cells

“…Trehalose is safe and approved as a food ingredient for human consumption by the European regulatory system and the U.S. Food and Drug Administration in 2000 [24]. This disaccharide is in use for topical and systemic treatment of ocular and systemic disorders, including oculopharyngeal muscular dystrophy, spinocerebellar atrophy type 3, atherosclerosis, fatty liver disease, dry eyes, and in the postsurgical management of laser-assisted in situ keratomileusis (LASIK) in multiple clinical trials [25][26][27][28],(https://clinicaltrials.gov/ct2/ show/NCT03700424; https://clinicaltrials.gov/ct2/show/NC T03738358). While autophagy upregulation by trehalose is well reported in many studies [23,29], a few reports have disputed this claim [30,31].…”

Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose

“… 35 The benefit of osmoprotectants in lubricant drops used to treat dry eye post-LASIK has also been demonstrated, with a significant improvement in symptoms reported following treatment with HA and adjuvant trehalose compared with HA alone. 36 …”